As i mentioned in the above thread, the doses that are in most CBD are merely a small fraction of what is being used in research.
- Most studies on CBD use very high doses, ranging from 100 mg to 1000 mg (or more) per day.
- Most supplements contained dosages of CBD between ~5 mg and ~23 mg per serving.
The study (posted below), which showed a benefit, was on anxiety and cravings in former opioid users. It used a dose of 400 or 800 mg which can be 20-40x (or more) what’s in an OTC dose and is what could be in 1/4 to 1/2 of a bottle of concentrated oil.
For example, this product, a concentrated extract, got one of the highest ratings at Consumerlab.
https://www.bluebird-botanicals.com/pro ... lassic-6x/It was also found to to have one of the lowest cost for CBD of those that passed independent testing.
A 1 oz bottle has 1500mg of CBD and costs $110. They say a serving has 25 mg and this is a concentrated product.
At a 400mg dose, as they used in the study, you get 3.75 doses per bottle, which is ~$30 a dose
At a 800mg dose, as used in the study, you get 1.87 doses per bottle, which is ~$60 a dose
In Health
Jeff
Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial
Published Online:21 May 2019
https://doi.org/10.1176/appi.ajp.2019.18101191Abstract
Objective:
Despite the staggering consequences of the opioid epidemic, limited nonopioid medication options have been developed to treat this medical and public health crisis. This study investigated the potential of cannabidiol (CBD), a nonintoxicating phytocannabinoid, to reduce cue-induced craving and anxiety, two critical features of addiction that often contribute to relapse and continued drug use, in drug-abstinent individuals with heroin use disorder.
Methods:
This exploratory double-blind randomized placebo-controlled trial assessed the acute (1 hour, 2 hours, and 24 hours), short-term (3 consecutive days), and protracted (7 days after the last of three consecutive daily administrations) effects of CBD administration (400 or 800 mg, once daily for 3 consecutive days) on drug cue–induced craving and anxiety in drug-abstinent individuals with heroin use disorder. Secondary measures assessed participants’ positive and negative affect, cognition, and physiological status.
Results:
Acute CBD administration, in contrast to placebo, significantly reduced both craving and anxiety induced by the presentation of salient drug cues compared with neutral cues. CBD also showed significant protracted effects on these measures 7 days after the final short-term (3-day) CBD exposure. In addition, CBD reduced the drug cue–induced physiological measures of heart rate and salivary cortisol levels. There were no significant effects on cognition, and there were no serious adverse effects.
Conclusions:
CBD’s potential to reduce cue-induced craving and anxiety provides a strong basis for further investigation of this phytocannabinoid as a treatment option for opioid use disorder.